Skip to main content
JSPR logo

JSPR · Jasper Therapeutics, Inc.

$0.60 -0.03 (-5.15%) At close · Jul 29
Market Cap
$17.72M
Shares
28.00M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.63 Open$0.67 Day$0.60–0.67 52W$0.32–3.25 Avg vol 30d2.0M Short int1.7M · 5.9% float · 1.9d Short vol29% Last earningsJun 12, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 14

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 14, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 20.7 · elevated Equity put/call 0.61
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −51%
below
Price vs 50-day avg +3%
above
RSI (14) 49
neutral
MACD trend Positive
52-week position 11%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +51%
trailing
6-month return −56%
trailing
YTD return −65%
this year
Relative strength −63%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
1 of 59 funds reported for Jun 30 · net -1 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
5.94% of float · ▼ -2.4% MoM · 1.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
59 holders — mid 2-yr range
Squeeze score 55
elevated · 0–100
Fundamentals
Excellent
EPS growth +19%
Y/Y
Balance sheet $28.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 99%
annualized · 1-yr
Max drawdown −89%
past year
ATR 17.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−51% Bearish
Price vs 50-day avg
+3% Bullish
RSI (14)
49 Neutral
MACD trend
Positive Bullish
52-week position
11% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
1 of 59 funds reported for Jun 30 · net -1 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
5.94% of float · ▼ -2.4% MoM · 1.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
59 holders — mid 2-yr range
Price context
position in its 52-week range
52-wk low $0 Now $1 · 11% 52-wk high $3
vs 200-day avg -51% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
JSPR
Jasper Therapeutics, Inc.
this stock
$17.72M -65.4% 5.9%
ONC
BeOne Medicines Ltd.
$472.90B +8.8% +22179.2% 962.4 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$124.46B +8.2% +46.2% 29.1 2.0%
REGN
Regeneron Pharmaceuticals, Inc.
$72.88B -9.8% +20.8% 17.0 3.3%
ARGX
Argenx SE
$54.57B +4.9% 2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
59
% held
57.0%
Reported
1 of 59
Top holder
Velan Capital Investment…
Held Float
View
Held by Funds
Fund positions
15
View
Short & Settlement
Short Interest Falling
Shares short
1.7M
Days to cover
1.9d
Change
-41.4K sh
View
Short Volume
Short vol %
29%
As of
Jul 29, 2026
Short Total
View
Fails to Deliver
FTD shares
3.5K
Value
$1.5K
As of
Jun 30, 2026
View
Off-Exchange
Off-exchange %
57.4%
Week of
May 4, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-76
EPS diluted
$-3.95
View
Filings
SEC Filings
Latest
8-K
Filed
Jul 17, 2026
This year
13
View
Proposed Sales
Value
$20.2K
Shares
900
Filed
Dec 12, 2024
View
Earnings & Events
Earnings Calls
Last call
Jun 12, 2026
View
Investor Relations
Latest news
Jasper Therapeutics Announces Mer…
Published
Jul 16, 2026
View

Performance

5D 20D 120D MTD YTD
JSPR -17.8% +50.7% -56.0% +50.4% -65.4%
SPY -1.0% 0.0% +7.4% -0.8% +8.6%
vs SPY -16.8% +50.7% -63.5% +51.2% -74.1%
Key facts CIK 1788028 CUSIP 471871202 13F (30d) 3 filings 3 filers Visit website Investor relations